^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients with Resectable Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial
Published date:
03/01/2023
Excerpt:
In this phase 2 trial, patients with histologically confirmed resectable stage IIA-IIIB NSCLC (stage IIIB, T3N2 only) received intravenous camrelizumab (200 mg) every 2 weeks for three cycles and oral apatinib (250 mg) once daily for 5 days followed by 2 days off for 6 weeks....Among 65 patients, 37 (57%, 95% CI 44%-69%) patients had an MPR, of whom 15 (23%, 95% CI 14%-35%) had a pathologic complete response (pCR). Pathologic responses observed in squamous-cell NSCLC were superior to adenocarcinoma (MPR: 64% vs. 25%; pCR: 23% vs. 0%)...baseline PD-L1 expression, HOXA9 and SEPT9 methylation levels, and ctDNA status before surgery were associated with pathologic responses.
DOI:
10.1016/j.jtho.2023.02.019
Source:
Title:
1267P - Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC
Published date:
09/14/2020
Excerpt:
...camrelizumab plus apatinib also demonstrated promising anti-tumor activity with acceptable safety in pts with advanced squamous NSCLC in terms of ORR, DCR and PFS, especially in those with PD-L1 positive tumors.
Trial ID:
